Bio Products La Patent-Cliff Exposure & CMS Drug Spending Portfolio
Bio Products La (US): 4 reconciled FDA prescription therapies, $363.9M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 4 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $363.9M |
| 2024 Medicare Part D Spend | $295.8M |
| 2024 Medicaid Spend | $68.1M |
| California HCAI SB 17 Filings | 6 WAC filings (max 16.4% 2-yr change) |